bezafibrate has been researched along with Alloxan Diabetes in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaneto, H; Matsuoka, TA; Miyatsuka, T; Shimo, N; Shimomura, I; Takahara, M; Takebe, S; Tochino, Y | 1 |
| Adamski, J; Aichler, M; Baumann, M; Beckers, J; Dubois, G; Feuchtinger, A; Franko, A; Fuchs, H; Gradinger, D; Hrabě de Angelis, M; Huypens, P; Irmler, M; Massinger, R; Neff, F; Neschen, S; Peter, A; Prehn, C; Prokisch, H; Przemeck, GK; Rathkolb, B; Repp, B; Rozman, J; Sanchez-Lasheras, C; Schommers, P; Schubert, M; Stöhr, O; Walch, AK; Wiesner, RJ; Wolf, E | 1 |
| Aichler, M; Brachthäuser, L; Feuchtinger, A; Franko, A; Fuchs, H; Häring, HU; Hrabě de Angelis, M; Kovarova, M; Neff, F; Neschen, S; Peter, A; Rathkolb, B; Rozman, J; Wolf, E | 1 |
| Kamata, K; Kanie, N; Kobayashi, T; Matsumoto, T | 1 |
| Akahane, S; Matsuzawa, A; Mori, Y; Oana, F; Tajima, N; Tokutate, Y | 1 |
| Esmat, AY; Gawad, SM; Ibrahim, AM; Mohamed, MA; Refaie, FM | 1 |
| Inoue, R; Kobara, M; Miki, S; Morita, Y; Murakami, M; Nakata, T; Nakayama, Y; Sawai, N; Shimizu, T; Toba, H; Tsukamoto, R; Yoshimura, A | 1 |
| Alam, MM; Anwer, T; Haque, SE; Pillai, KK; Sharma, M; Zaman, MS | 1 |
8 other study(ies) available for bezafibrate and Alloxan Diabetes
| Article | Year |
|---|---|
Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key β-cell factors under diabetic conditions.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Bezafibrate; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gene Expression; Glucose; Glucosides; Hypoglycemic Agents; Islets of Langerhans; Lipids; Mice | 2015 |
Bezafibrate Improves Insulin Sensitivity and Metabolic Flexibility in STZ-Induced Diabetic Mice.
Topics: Animals; Bezafibrate; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Humans; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Liver; Male; Metabolomics; Mice; Mice, Inbred C57BL; Mitochondria, Liver; Oligonucleotide Array Sequence Analysis; Oxygen Consumption; Peroxisome Proliferator-Activated Receptors | 2016 |
Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease Models, Animal; Fatty Liver; Glucose; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Peroxisome Proliferator-Activated Receptors | 2017 |
Relationship between peroxisome proliferator-activated receptors (PPAR alpha and PPAR gamma) and endothelium-dependent relaxation in streptozotocin-induced diabetic rats.
Topics: Animals; Aorta; Bezafibrate; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Endothelium, Vascular; In Vitro Techniques; Male; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Vasodilation | 2003 |
Bezafibrate-induced changes over time in the expression of uncoupling protein (UCP) mRNA in the tissues: a study in spontaneously type 2 diabetic rats with visceral obesity.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Carrier Proteins; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Eating; Fatty Acids; Gene Expression Regulation; Hypolipidemic Agents; Insulin; Ion Channels; Leptin; Male; Membrane Proteins; Membrane Transport Proteins; Mitochondrial Proteins; Obesity; PPAR alpha; PPAR delta; Rats; Rats, Inbred Strains; RNA, Messenger; Thyroid Hormones; Uncoupling Agents; Uncoupling Protein 1; Uncoupling Protein 2; Uncoupling Protein 3; Viscera | 2004 |
The antihyperlipidemic activities of 4(3H) quinazolinone and two halogenated derivatives in rats.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Cholesterol, Dietary; Diabetes Mellitus, Experimental; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Malondialdehyde; Quinazolines; Quinazolinones; Rats | 2005 |
The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta, Thoracic; Bezafibrate; Blood Glucose; Blotting, Western; Diabetes Mellitus, Experimental; Gene Expression; Hypoglycemic Agents; Hypolipidemic Agents; Injections, Intraperitoneal; Insulin; Lipid Metabolism; Male; NADPH Oxidase 4; NADPH Oxidases; Osteopontin; Peptidyl-Dipeptidase A; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazolidinediones; Vascular Cell Adhesion Molecule-1 | 2006 |
Protective effect of bezafibrate on streptozotocin-induced oxidative stress and toxicity in rats.
Topics: Administration, Oral; Animals; Antioxidants; Bezafibrate; Blood Glucose; Catalase; Diabetes Mellitus, Experimental; Glutathione; Glutathione Peroxidase; Hyperglycemia; Hypolipidemic Agents; Injections, Intraperitoneal; Insulin-Secreting Cells; Islets of Langerhans; Lipid Peroxidation; Liver; Male; Malondialdehyde; Oxidative Stress; Rats; Rats, Wistar; Streptozocin; Superoxide Dismutase; Time Factors | 2007 |